The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Survival differences in patients (pts) with resected rectal cancer who received neoadjuvant therapy with or without postoperative chemotherapy (CT).
Christina Sing-Ying Wu
No relevant relationships to disclose
Lai Wei
No relevant relationships to disclose
Katherine Glass
No relevant relationships to disclose
John Wilson
No relevant relationships to disclose
Sherif Abdel-Misih
No relevant relationships to disclose
Ludmila Katherine Martin
No relevant relationships to disclose
Sigurdis Haraldsdottir
No relevant relationships to disclose
Alan Harzman
No relevant relationships to disclose
Syed Husain
No relevant relationships to disclose
Carl Richard Schmidt
No relevant relationships to disclose
Mark Arnold
No relevant relationships to disclose
Richard M. Goldberg
Consultant or Advisory Role - Bayer (U); Jennerex Biotherapeutics (U); Lilly; Myriad Genetics (U); Sanofi (U)
Research Funding - Bayer (I); Sanofi
Tanios S. Bekaii-Saab
Consultant or Advisory Role - Amgen; Bristol-Myers Squibb; Genentech; Sanofi